Scoop: Bing Yao’s ArriVent lining up $145M raise, after $150M debut in 2021
Bing Yao took his previous biotech through three key milestones: IPO, drug approval and an M&A exit. Now, he’s lining up another round of financing for his bet on bringing Chinese R&D to the States.
ArriVent Biopharma debuted with a $150 million round in June 2021. New paperwork filed with the SEC last week outlines a second round of financing is in the works for up to $145 million. The filing documents 17 investors so far lining up $110 million.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.